Efficacy of lamivudine for prevention of hepatitis B virus reinfection after liver transplantation
- VernacularTitle:拉米夫定预防肝移植术后乙型肝炎病毒再感染的研究
- Author:
Jie XIA
;
Yonggang WANG
;
Yuming WANG
- Publication Type:Journal Article
- Keywords:
Liver transplantation;
Lamivudine;
Hepatitis B virus;
DNA
- From:
Chinese Journal of Organ Transplantation
1996;0(03):-
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of lamivudine for the prevention of hepatitis Bvirus reinfection in post-orthotopic liver transplantation (OLT) patients.Methods Clinical data of 41adult patients followed up for 2 years after liver transplantation,who received lamivudine prophylactic strategy for HBV reinfection,were analyzed retrospectively.Results Ten cases developed hepatitis B virus(HBV) reinfection,and 9 of them were caused by LAM-resistant HBV(YMDD).The one-and 2-year rate of HBV reinfection after transplantation was(9.8 %)(4/41) and(24.4 %)(10/41) respectively.The reinfection rate of group with negative preOLT serum HBV DNA was much lower than in the HBV DNA positive group.The reinfection rate of group receiving long-term(more than 6 months) lamivudine treatment and group not receiving anti-virus treatment pre-OLT was(66.7 %) and(23.1 %),respectively.Both of them were remarkably higher than in the group receiving short-term less than 6 months lamivudine treatment.Conclusions The short-term(less than 6 months) lamivudine treatment pre-OLT can suppress serum HBV DNA replication effectively,and long-term more than 6 months lamivudine treatment pre-OLT can decline the rate of HBV reinfection obviously.But the prophylaxis of long-term LAM monotherapy may induce LAM-resistant HBV variants(YMDD) reinfection.
